AI Article Synopsis

  • HIV antigens can be detected in individuals with HIV infection even before antibodies develop or after they decline during late-stage infection.
  • Researchers tested plasma samples and cell extracts from HIV-positive individuals and healthy donors to improve the detection of these antigens.
  • All infected subjects tested positive for HIV antigens in at least one sample type, while none of the healthy donors tested positive, suggesting this method could help in unclear antibody test cases.

Article Abstract

Antigenaemia due to human immunodeficiency virus (HIV) is thought to be significant either before the appearance of a specific antibody response, or after its decline during terminal stages. In order to increase the rate of detection of HIV antigen carriers, regardless of the stage or despite the presence of specific serum antibodies, we assayed, simultaneously, plasma samples and extracts from resting and phytohaemagglutinin-stimulated mononuclear cells from 25 infected, anti-body-positive individuals and 10 healthy, antibody-negative female volunteer blood donors. We detected the presence of HIV antigen in at least one of the three types of specimens obtained from all the 25 infected subjects but in none of the 10 healthy blood donors. This approach might prove most useful for the study of patients with controversial or equivocal antibody test results.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0166-0934(88)90115-2DOI Listing

Publication Analysis

Top Keywords

human immunodeficiency
8
immunodeficiency virus
8
antigen carriers
8
extracts resting
8
resting phytohaemagglutinin-stimulated
8
mononuclear cells
8
hiv antigen
8
blood donors
8
increased detection
4
detection human
4

Similar Publications

[Men who have sex with men negotiating pleasure and prevention through HIV pre-exposure prophylaxis].

Cien Saude Colet

January 2025

Faculdade de Medicina, Universidade de São Paulo. Av. Dr. Arnaldo 455, 2º andar, sala 2216, Cerqueira Cesar. 01246-903 São Paulo SP Brasil.

Prophylaxis based on antiretrovirals, such as pre-exposure prophylaxis to HIV (PrEP), has the potential to protect the populations most vulnerable to infection, which renews optimism for controlling the HIV epidemic. Against this backdrop, the aim of this article is to analyze the perceptions, negotiations and tensions surrounding the use of PrEP by men who have sex with men (MSM). This is a qualitative cross-section of a multicenter study, analyzing semi-structured interviews with 18 users of specialized HIV/AIDS healthcare facilities in the city of São Paulo/SP.

View Article and Find Full Text PDF

Background: Antiretroviral treatment increases the risk of accumulation of resistance mutations that negatively impact the possibilities of future treatment. This study aimed to present the frequency of HIV-1 antiretroviral resistance mutations and the genetic diversity among children with virological failure in five pediatric care facilities in Benin.

Methods: A cross-sectional study was carried out from November 20, 2020, to November 30, 2022, in children under 15 years of age who failed ongoing antiretroviral treatment at five facilities care in Benin (VL > 3log10 on two consecutive realizations three months apart).

View Article and Find Full Text PDF

Purpose: Adolescent girls are at high risk for depression and human immunodeficiency virus (HIV) acquisition. Poor mental health can increase vulnerability to risky sexual behaviours. Therefore, this study aims to determine the prevalence of depressive symptomology and explore the convergence of HIV risk factors with depressive symptoms amongst cis-gender adolescent girls and young women (AGYW) in rural KwaZulu-Natal (KZN) and peri-urban Western Cape (WC) communities in South Africa.

View Article and Find Full Text PDF

Many HIV clinics with poor IT-infrastructure are unable to report data on individuals in care with HIV, on antiretroviral treatment (ART) and virologically suppressed (VS), with the aim of monitoring the HIV Continuum of Care to estimate efficacy of HIV treatment programmes. We developed an estimation-tool, ESTIHIV, and determined the minimal data required for a random sample, to produce representative estimates, with a specified level of precision, of people with HIV on ART and VS. For proof of concept, 8852 HIV positive persons from seven clinics in seven different countries, with a follow-up visit during 2017, were included.

View Article and Find Full Text PDF

Background: Malaria and HIV are leading causes of death in Africa, including Cameroon. Antiretroviral therapy (ART) is expected to boost immunity and reduce vulnerability to opportunistic infections. Reports on comorbidities including malaria are common in Cameroon.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!